- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ) (the "Company"), a U.
S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.
2) and 4-1BB bispecific antibody, at SITC 2024. The conference is being held in Houston, Texas , from November 6-10, 2024 . Presentation Details: Title: Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.
2×4-1BB bispecific antibody Poster #: 1474 Presenter : J.A. Yanez, I-Mab Session : Poster Hall, George R.
Brown Convention Center Session Date : Saturday, November 9, 2024 Session Time : 9:00 am CDT to 8:30 pm CDT , Level 1 – Exhibit Halls AB A full copy of the poster will be available on the I-Mab website under the "Innovation, Publications & Presentations" tab on November 9, 2024 . About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells.
It conditionally activates T cells through the 4-1BB pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig appears to maintain strong tumor bindi.